Aclaris Therapeutics, Inc. (ACRS): Insider Trading, Congress Trades & Research | Tormere

ACRS

$3.74-1.58%visit website

Aclaris Therapeutics, Inc.

Market Cap

$551M

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.97

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

67.0

TTM to Jun 2026 · revenue

P/B

4.4

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	3,299	1,295	1,996	1,629	8,219
Cost of revenue	538	532	395	218	1,683
Research & development	13,028	16,584	15,657	18,066	63,335
Operating income	(17,149)	(22,734)	(22,192)	(24,238)	(86,313)
Pretax income	(14,614)	(19,795)
Net income	(14,614)	(19,795)	(19,824)	(21,505)	(75,738)
EPS (basic) ($)	(0.12)		(0.15)	(0.15)	(0.58)
EPS (diluted) ($)	(0.12)		(0.15)	(0.15)	(0.58)
Weighted avg. shares (basic)	122,619		128,810	142,737
Weighted avg. shares (diluted)	122,619		128,810	142,737

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 46 more quarters, back to Mar 2014, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

18 analysts

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-04-23	2026-04-27	Leonard Braden Michael	10% Owner	Sale	300.0K	$4.53	$1.36M	13.95M	View

Recent News

Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13

Benzinga · 2026-10-30

Aclaris Therapeutics (NasdaqGS:ACRS) Stock Forecast & Analyst Predictions

Simply Wall St · 2026-10-30

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow (NASDAQ:ACRS) 2026-10-29

Seeking Alpha · 2026-10-29

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma - Slideshow

SeekingAlpha · 2026-10-29

Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8

Benzinga · 2026-10-28

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

Benzinga · 2026-10-28

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Yahoo · 2026-10-27

Aclaris Therapeutics Reports Positive Phase 1b ATI-052 Trial Results, Prices $50 Million Offering

Yahoo · 2026-10-27

Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug

Benzinga · 2026-10-27

Aclaris Reports Positive Asthma, Eczema Drug Trial Results — So, Why Is ACRS Stock Down Nearly 8%?

Yahoo · 2026-10-27

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

SeekingAlpha · 2026-10-27

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

Yahoo · 2026-10-27

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Yahoo · 2026-10-27

Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Benzinga · 2026-10-27

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Yahoo Finance · 2026-10-21

Informational purposes only, not investment advice.

Corporate Events (8-K)

2 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 27, 2026 accepted 5:25 PM ET	1.01Material agreement	Document SEC ↗
Oct 27, 2026 accepted 6:06 AM ET	2.02Earnings release7.01Reg FD disclosure8.01Other events	Document SEC ↗